{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:18Z","timestamp":1791476058522,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,16]]},"DOI":"10.7759\/cureus.79097","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T17:50:26Z","timestamp":1739728226000},"source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Advancements in the Management of Psoriasis: A Clinical Overview and Update"],"prefix":"10.7759","author":[{"given":"Sarah F","family":"Qasem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Ashkanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi R","year":"2020","unstructured":"Parisi R, Iskandar IY, Kontopantelis E, Augustin M, Griffiths CE, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020, 369:10.1136\/bmj.m1590","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000247341","article-title":"Bimodality in age of onset of psoriasis, in both patients and their relatives","volume":"186","author":"Smith AE","year":"1993","unstructured":"Smith AE, Kassab JY, Rowland Payne CM, Beer WE. Bimodality in age of onset of psoriasis, in both patients and their relatives. Dermatology. 1993, 186:181-6. 10.1159\/000247341","journal-title":"Dermatology"},{"key":"ref3","article-title":"Psoriasis and psoriatic arthritis overview","volume":"22","author":"Menter A","year":"2016","unstructured":"Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016, 22:216-24.","journal-title":"Am J Manag Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes JE","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017, 140:645-53. 10.1016\/j.jaci.2017.07.004","journal-title":"J Allergy Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.768","article-title":"Pruritus in psoriasis: an update","volume":"20","author":"Szepietowski JC","year":"2016","unstructured":"Szepietowski JC, Reich A. Pruritus in psoriasis: an update. Eur J Pain. 2016, 20:41-6. 10.1002\/ejp.768","journal-title":"Eur J Pain"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon A","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. J Prim Care Community Health. 2019, 20:6. 10.3390\/ijms20061475","journal-title":"J Prim Care Community Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama M","year":"2020","unstructured":"Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020, 21:10.3390\/ijms21207488","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/life11070627","article-title":"A new classification of the severity of psoriasis: what's moderate psoriasis?","volume":"11","author":"Salgado-Boquete L","year":"2021","unstructured":"Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la Cueva P, Belinch\u00f3n I. A new classification of the severity of psoriasis: what's moderate psoriasis?. Life (Basel). 2021, 11:10.3390\/life11070627","journal-title":"Life (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5455\/msm.2014.26.168-171","article-title":"An epidemiological study on trigger factors and quality of life in psoriatic patients","volume":"26","author":"Xhaja A","year":"2014","unstructured":"Xhaja A, Shkodrani E, Frangaj S, Kuneshka L, Vasili E. An epidemiological study on trigger factors and quality of life in psoriatic patients. Mater Sociomed. 2014, 26:168-71. 10.5455\/msm.2014.26.168-171","journal-title":"Mater Sociomed"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020, 323:1945-60. 10.1001\/jama.2020.4006","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2008.01.015","article-title":"Emollients, moisturizers, and keratolytic agents in psoriasis","volume":"26","author":"Fluhr JW","year":"2008","unstructured":"Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008, 26:380-6. 10.1016\/j.clindermatol.2008.01.015","journal-title":"Clin Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1214-8","article-title":"German S3-guidelines on the treatment of psoriasis vulgaris (short version)","volume":"304","author":"Nast A","year":"2012","unstructured":"Nast A, Boehncke WH, Mrowietz U, et al.. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012, 304:87-113. 10.1007\/s00403-012-1214-8","journal-title":"Arch Dermatol Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette R","year":"2021","unstructured":"Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021, 84:1059-67. 10.1016\/j.jaad.2020.10.085","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl MG","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Strober B, et al.. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021, 385:2219-29. 10.1056\/NEJMoa2103629","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.061","article-title":"Tapinarof cream 1% once daily for the treatment of plaque psoriasis: patient-reported outcomes from the PSOARING 3 trial","volume":"89","author":"Bagel J","year":"2023","unstructured":"Bagel J, Gold LS, Del Rosso J, et al.. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023, 89:936-44. 10.1016\/j.jaad.2023.04.061","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING\u00a03 trial","volume":"87","author":"Strober B","year":"2022","unstructured":"Strober B, Stein Gold L, Bissonnette R, et al.. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING\u00a03 trial. J Am Acad Dermatol. 2022, 87:800-6. 10.1016\/j.jaad.2022.06.1171","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S303634","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"11","author":"Milakovic M","year":"2021","unstructured":"Milakovic M, Gooderham MJ. Phosphodiesterase-4 inhibition in psoriasis. Psoriasis (Auckl). 2021, 11:21-9. 10.2147\/PTT.S303634","journal-title":"Psoriasis (Auckl)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials","volume":"328","author":"Lebwohl MG","year":"2022","unstructured":"Lebwohl MG, Kircik LH, Moore AY, et al.. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022, 328:1073-84. 10.1001\/jama.2022.15632","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009687.pub2","article-title":"Topical treatments for scalp psoriasis","volume":"2","author":"Schlager JG","year":"2016","unstructured":"Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A. Topical treatments for scalp psoriasis. Cochrane Database Syst Rev. 2016, 2:10.1002\/14651858.CD009687.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct072317","article-title":"Psoralen and ultraviolet a light therapy for psoriasis","volume":"357","author":"Stern RS","year":"2007","unstructured":"Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med. 2007, 357:682-90. 10.1056\/NEJMct072317","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2005.05025.x","article-title":"Treating vascular lesions","volume":"18","author":"Astner S","year":"2005","unstructured":"Astner S, Anderson RR. Treating vascular lesions. Dermatol Ther. 2005, 18:267-81. 10.1111\/j.1529-8019.2005.05025.x","journal-title":"Dermatol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter A","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al.. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019, 80:1029-72. 10.1016\/j.jaad.2018.11.057","journal-title":"J Am Acad Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp K","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al.. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015, 73:37-49. 10.1016\/j.jaad.2015.03.049","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0062","article-title":"Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary","volume":"15","author":"Strober B","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al.. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. 2023, 15:787-97. 10.2217\/imt-2023-0062","journal-title":"Immunotherapy"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith CH","year":"2020","unstructured":"Smith CH, Yiu ZZ, Bale T, et al.. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020, 183:628-37. 10.1111\/bjd.19039","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.4956","article-title":"Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study","volume":"151","author":"Shalom G","year":"2015","unstructured":"Shalom G, Zisman D, Bitterman H, et al.. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol. 2015, 151:533-8. 10.1001\/jamadermatol.2014.4956","journal-title":"JAMA Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber W","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al.. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012, 61:1693-700. 10.1136\/gutjnl-2011-301668","journal-title":"Gut"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi CL","year":"2003","unstructured":"Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003, 349:2014-22. 10.1056\/NEJMoa030409","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich K","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al.. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017, 390:276-88. 10.1016\/S0140-6736(17)31279-5","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari U","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001, 357:1842-7. 10.1016\/s0140-6736(00)04954-0","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384","article-title":"Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial","volume":"147","author":"Leonardi C","year":"2011","unstructured":"Leonardi C, Langley RG, Papp K, et al.. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011, 147:429-36. 10.1001\/archdermatol.2010.384","journal-title":"Arch Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis - results of two phase 3 trials","volume":"371","author":"Langley RG","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al.. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med. 2014, 371:326-38. 10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon KB","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al.. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016, 375:345-56. 10.1056\/NEJMoa1512711","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl M","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al.. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015, 373:1318-28. 10.1056\/NEJMoa1503824","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S367744","article-title":"Bimekizumab for the treatment of psoriasis: a review of the current knowledge","volume":"12","author":"Ruggiero A","year":"2022","unstructured":"Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis (Auckl). 2022, 12:127-37. 10.2147\/PTT.S367744","journal-title":"Psoriasis (Auckl)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren RB","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al.. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021, 385:130-41. 10.1056\/NEJMoa2102388","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial","volume":"89","author":"Strober B","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, et al.. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023, 89:486-95. 10.1016\/j.jaad.2023.04.063","journal-title":"J Am Acad Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich K","year":"2020","unstructured":"Reich K, Warren RB, Iversen L, et al.. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020, 182:605-17. 10.1111\/bjd.18232","journal-title":"Br J Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich K","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al.. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019, 394:576-86. 10.1016\/S0140-6736(19)30952-3","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/331033-therapeutic-advancements-in-the-management-of-psoriasis-a-clinical-overview-and-update","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T17:50:28Z","timestamp":1739728228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/331033-therapeutic-advancements-in-the-management-of-psoriasis-a-clinical-overview-and-update"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,16]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.79097","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,16]]}}}